International Intraductal Papillary Mucinous Neoplasms Registry: Long-Term Results Based on the New Guidelines

Maria Moris, Massimo Raimondo, Timothy A. Woodward, Verna J. Skinner, Paolo G. Arcidiacono, Maria C. Petrone, Claudio de Angelis, Selene Manfrè, Silvia Carrara, Manol Jovani, Pietro Fusaroli, Michael B. Wallace

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

OBJECTIVE: The aim of this study was to analyze the outcomes of a long-term intraductal papillary mucinous neoplasm (IPMN) registry and evaluate new guidelines. METHODS: A prospectively maintained IPMN registry involving 6 centers in Europe and the United States was used to collect the data. Patients with more than 1-year follow-up and no malignancy diagnosed within the first 3 months of surveillance were included. RESULTS: From 1999 to 2014, 620 patients were included. The median follow-up time was 3 years. Thirty-seven (6%) patients developed malignancy with a median time from IPMN diagnosis to malignancy of 10.3 months. The 1-, 5-, and 10-year actuarial rates of disease-free survival were 97%, 93%, and 92% respectively. Four hundred thirty-one patients met criteria for low-risk branch duct IPMN consisting of cyst size less than 3 cm, with no solid component or main duct dilation. Eight malignancies were diagnosed in this subgroup, all of them within the first 5 years. From this subcohort, 112 patients had a follow-up time of more than 5 years, and no malignancy was diagnosed. CONCLUSIONS: In IPMN lesions with low-risk features at baseline, the risk of progression to malignancy after the first 5 years of follow-up was minimal. Furthermore, the main cyst characteristics remained unchanged during their surveillance.

Original languageEnglish (US)
JournalPancreas
DOIs
StateAccepted/In press - Jan 18 2017

Fingerprint

Registries
Guidelines
Neoplasms
Cysts
Disease-Free Survival
Dilatation

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

Moris, M., Raimondo, M., Woodward, T. A., Skinner, V. J., Arcidiacono, P. G., Petrone, M. C., ... Wallace, M. B. (Accepted/In press). International Intraductal Papillary Mucinous Neoplasms Registry: Long-Term Results Based on the New Guidelines. Pancreas. https://doi.org/10.1097/MPA.0000000000000750

International Intraductal Papillary Mucinous Neoplasms Registry : Long-Term Results Based on the New Guidelines. / Moris, Maria; Raimondo, Massimo; Woodward, Timothy A.; Skinner, Verna J.; Arcidiacono, Paolo G.; Petrone, Maria C.; de Angelis, Claudio; Manfrè, Selene; Carrara, Silvia; Jovani, Manol; Fusaroli, Pietro; Wallace, Michael B.

In: Pancreas, 18.01.2017.

Research output: Contribution to journalArticle

Moris, M, Raimondo, M, Woodward, TA, Skinner, VJ, Arcidiacono, PG, Petrone, MC, de Angelis, C, Manfrè, S, Carrara, S, Jovani, M, Fusaroli, P & Wallace, MB 2017, 'International Intraductal Papillary Mucinous Neoplasms Registry: Long-Term Results Based on the New Guidelines', Pancreas. https://doi.org/10.1097/MPA.0000000000000750
Moris, Maria ; Raimondo, Massimo ; Woodward, Timothy A. ; Skinner, Verna J. ; Arcidiacono, Paolo G. ; Petrone, Maria C. ; de Angelis, Claudio ; Manfrè, Selene ; Carrara, Silvia ; Jovani, Manol ; Fusaroli, Pietro ; Wallace, Michael B. / International Intraductal Papillary Mucinous Neoplasms Registry : Long-Term Results Based on the New Guidelines. In: Pancreas. 2017.
@article{684ee19e1d4e4bed8672e34f7d77e214,
title = "International Intraductal Papillary Mucinous Neoplasms Registry: Long-Term Results Based on the New Guidelines",
abstract = "OBJECTIVE: The aim of this study was to analyze the outcomes of a long-term intraductal papillary mucinous neoplasm (IPMN) registry and evaluate new guidelines. METHODS: A prospectively maintained IPMN registry involving 6 centers in Europe and the United States was used to collect the data. Patients with more than 1-year follow-up and no malignancy diagnosed within the first 3 months of surveillance were included. RESULTS: From 1999 to 2014, 620 patients were included. The median follow-up time was 3 years. Thirty-seven (6{\%}) patients developed malignancy with a median time from IPMN diagnosis to malignancy of 10.3 months. The 1-, 5-, and 10-year actuarial rates of disease-free survival were 97{\%}, 93{\%}, and 92{\%} respectively. Four hundred thirty-one patients met criteria for low-risk branch duct IPMN consisting of cyst size less than 3 cm, with no solid component or main duct dilation. Eight malignancies were diagnosed in this subgroup, all of them within the first 5 years. From this subcohort, 112 patients had a follow-up time of more than 5 years, and no malignancy was diagnosed. CONCLUSIONS: In IPMN lesions with low-risk features at baseline, the risk of progression to malignancy after the first 5 years of follow-up was minimal. Furthermore, the main cyst characteristics remained unchanged during their surveillance.",
author = "Maria Moris and Massimo Raimondo and Woodward, {Timothy A.} and Skinner, {Verna J.} and Arcidiacono, {Paolo G.} and Petrone, {Maria C.} and {de Angelis}, Claudio and Selene Manfr{\`e} and Silvia Carrara and Manol Jovani and Pietro Fusaroli and Wallace, {Michael B.}",
year = "2017",
month = "1",
day = "18",
doi = "10.1097/MPA.0000000000000750",
language = "English (US)",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - International Intraductal Papillary Mucinous Neoplasms Registry

T2 - Long-Term Results Based on the New Guidelines

AU - Moris, Maria

AU - Raimondo, Massimo

AU - Woodward, Timothy A.

AU - Skinner, Verna J.

AU - Arcidiacono, Paolo G.

AU - Petrone, Maria C.

AU - de Angelis, Claudio

AU - Manfrè, Selene

AU - Carrara, Silvia

AU - Jovani, Manol

AU - Fusaroli, Pietro

AU - Wallace, Michael B.

PY - 2017/1/18

Y1 - 2017/1/18

N2 - OBJECTIVE: The aim of this study was to analyze the outcomes of a long-term intraductal papillary mucinous neoplasm (IPMN) registry and evaluate new guidelines. METHODS: A prospectively maintained IPMN registry involving 6 centers in Europe and the United States was used to collect the data. Patients with more than 1-year follow-up and no malignancy diagnosed within the first 3 months of surveillance were included. RESULTS: From 1999 to 2014, 620 patients were included. The median follow-up time was 3 years. Thirty-seven (6%) patients developed malignancy with a median time from IPMN diagnosis to malignancy of 10.3 months. The 1-, 5-, and 10-year actuarial rates of disease-free survival were 97%, 93%, and 92% respectively. Four hundred thirty-one patients met criteria for low-risk branch duct IPMN consisting of cyst size less than 3 cm, with no solid component or main duct dilation. Eight malignancies were diagnosed in this subgroup, all of them within the first 5 years. From this subcohort, 112 patients had a follow-up time of more than 5 years, and no malignancy was diagnosed. CONCLUSIONS: In IPMN lesions with low-risk features at baseline, the risk of progression to malignancy after the first 5 years of follow-up was minimal. Furthermore, the main cyst characteristics remained unchanged during their surveillance.

AB - OBJECTIVE: The aim of this study was to analyze the outcomes of a long-term intraductal papillary mucinous neoplasm (IPMN) registry and evaluate new guidelines. METHODS: A prospectively maintained IPMN registry involving 6 centers in Europe and the United States was used to collect the data. Patients with more than 1-year follow-up and no malignancy diagnosed within the first 3 months of surveillance were included. RESULTS: From 1999 to 2014, 620 patients were included. The median follow-up time was 3 years. Thirty-seven (6%) patients developed malignancy with a median time from IPMN diagnosis to malignancy of 10.3 months. The 1-, 5-, and 10-year actuarial rates of disease-free survival were 97%, 93%, and 92% respectively. Four hundred thirty-one patients met criteria for low-risk branch duct IPMN consisting of cyst size less than 3 cm, with no solid component or main duct dilation. Eight malignancies were diagnosed in this subgroup, all of them within the first 5 years. From this subcohort, 112 patients had a follow-up time of more than 5 years, and no malignancy was diagnosed. CONCLUSIONS: In IPMN lesions with low-risk features at baseline, the risk of progression to malignancy after the first 5 years of follow-up was minimal. Furthermore, the main cyst characteristics remained unchanged during their surveillance.

UR - http://www.scopus.com/inward/record.url?scp=85009808665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009808665&partnerID=8YFLogxK

U2 - 10.1097/MPA.0000000000000750

DO - 10.1097/MPA.0000000000000750

M3 - Article

C2 - 28099263

AN - SCOPUS:85009808665

JO - Pancreas

JF - Pancreas

SN - 0885-3177

ER -